Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT05646563Phase 2Not yet recruiting
- Sponsor
- NovelMed Therapeutics
- Start
- Jan 2027
- Primary completion
- Jul 2029
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ruxoprubart in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by NovelMed Therapeutics. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
ruxoprubart
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05646563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05646563.